[Mechanism and clinical treatment strategy of heparin resistance].

Men, J L; Xu, F Y; Zhai, Z G

Men, J L; Xu, F Y; Zhai, Z G.

Afiliación

Men JL; Precision Medicine Center, Tianjin Medical University General Hospital, Tianjin 300052, China.
Xu FY; China-Japan Friendship Clinical Medical College, Capital Medical University, Beijing 100069, China.
Zhai ZG; Center of Respiratory Medicine, China-Japan Friendship Hospital; National Clinical Research Center for Respiratory Diseases; Department of Pulmonary and Critical Care Medicine, Beijing 100029, China.

Zhonghua Yi Xue Za Zhi ; 103(0): 707-713, 2023 Jan 10.

Article en Zh | MEDLINE | ID: mdl-36634914

Asunto(s)

COVID-19; Heparina; Humanos; Heparina/uso terapéutico; Heparina/efectos adversos; Anticoagulantes/uso terapéutico; Antitrombinas; Tiempo de Tromboplastina Parcial; Estudios Retrospectivos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Heparina / COVID-19 Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: Zh Revista: Zhonghua Yi Xue Za Zhi Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google